Related Experiment Videos

Active replication of hepatitis B virus (HBV) in HIV type 1 and in HIV type 2 infected patients

M F Barros1, J Piedade, G Nunes

  • 1Serviço de Imunologia, Faculdade de Ciências Médicas, Universidade Nova de Lisboa (UNL), Portugal.

Insights

Concurrent human immunodeficiency virus (HIV) infection does not correlate with hepatitis B virus (HBV) active replication. HIV-infected individuals may maintain sufficient immunity to prevent HBV reactivation or reinfection.

Area of Science:

  • Virology
  • Immunology
  • Public Health

Background:

  • Concurrent infections with human immunodeficiency virus (HIV) and hepatitis B virus (HBV) are common globally.
  • Understanding the impact of HIV on HBV status is crucial for managing co-infected individuals and informing public health strategies.

Purpose of the Study:

  • To evaluate the effect of concurrent HIV infection on HBV infection and immunity.
  • To assess the prevalence of HBV active replication in HIV-positive individuals compared to HIV-negative controls.

Main Methods:

  • Serological markers of HBV infection and HBV DNA in serum were monitored in 66 HIV-1 positive Caucasian patients and 38 HIV-2 positive asymptomatic African individuals.
  • HIV-positive groups were compared with age, sex, and ethnologically matched seronegative controls.
  • HBV DNA presence in serum was used as an indicator of active hepatitis B virus replication.

Main Results:

  • No significant correlation was found between HIV infection and HBV active replication.
  • HBV DNA was detected in 7.6% of HIV-1+ Caucasian patients and 3.2% of seronegative controls.
  • In African HIV-2+ individuals, 2.6% were HBV DNA positive, similar to HIV-2 seronegative controls (2.9%).

Conclusions:

  • HIV infection does not appear to increase the risk of HBV active replication.
  • The immune system, even in symptomatic HIV infection, may retain sufficient function to prevent HBV reactivation or reinfection.
  • Findings are relevant for developing preventive strategies in populations at risk for both HIV and HBV.

Related Concept Videos